KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Change in Cash (2016 - 2025)

Boston Scientific (BSX) has disclosed Change in Cash for 17 consecutive years, with $671.0 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 132.83% to $671.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, up 442.44% year-over-year, with the annual reading at $1.5 billion for FY2025, 442.44% up from the prior year.
  • Change in Cash hit $671.0 million in Q4 2025 for Boston Scientific, down from $735.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $1.4 billion in Q1 2024 to a low of -$2.0 billion in Q4 2024.
  • Historically, Change in Cash has averaged $7.6 million across 5 years, with a median of $24.0 million in 2021.
  • Biggest five-year swings in Change in Cash: skyrocketed 6888.89% in 2022 and later tumbled 2554.55% in 2024.
  • Year by year, Change in Cash stood at $9.0 million in 2021, then surged by 6888.89% to $629.0 million in 2022, then crashed by 112.24% to -$77.0 million in 2023, then crashed by 2554.55% to -$2.0 billion in 2024, then surged by 132.83% to $671.0 million in 2025.
  • Business Quant data shows Change in Cash for BSX at $671.0 million in Q4 2025, $735.0 million in Q3 2025, and -$179.0 million in Q2 2025.